Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Association between PD-L1 expression with EGFR, ALK, and ROS1 driver oncogene mutations in non-small cell lung cancer

20 Jun 2024

Abstract excerpt

BACKGROUND: Driver mutations and immunological expressions have gained importance in recent years for targeted therapies and immunotherapies of nonsmall cell lung cancer (NSCLC). AIMS: This study examined the association between PD-L1 expression and ALK , ROS1 , and EGFR driver oncogene mutations in patients with NSCLC. MATERIALS AND METHODS: A total of 501 NSCLC patients were included for analysis....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Lung Cancer Diagnosis and Treatment
Share to Lung Cancer Treatments and Mutations

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38904451
DOI: 10.4103/ijpm.ijpm_939_23

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Association between PD-L1 expression with EGFR, ALK, and ROS1 driver oncogene mutations in non-small cell lung cancerPMID 38904451Read ↗

Association of PD-L1 expression with driver gene mutations and clinicopathological characteristics in non-small cell lung cancer: A real-world study of 10 441 patients.Semantic proximity Read ↗

PD-L1 expression and its correlation with clinicopathological and molecular characteristics in Chinese patients with non-small cell lung cancer.Semantic proximity Read ↗

PD-L1 expression and its clinicopathologic and genomic correlation in the non-small cell lung carcinoma patients: An Indian perspective.Semantic proximity Read ↗

Clinicopathological and molecular characteristics associated with PD-L1 expression in non-small cell lung cancer: a large-scale, multi-center, real-world study in China.Semantic proximity Read ↗

Association between PD-L1 expression and driver gene mutations in non-small cell lung cancer patients: correlation with clinical data.Semantic proximity Read ↗

Various impacts of driver mutations on the PD-L1 expression of NSCLC.Semantic proximity Read ↗

Comprehensive analysis of PD-L1 in non-small cell lung cancer with emphasis on survival benefit, impact of driver mutation and histological types, and archival tissue.Semantic proximity Read ↗

PD-L1 Expression and Comprehensive Molecular Profiling Predict Survival in Nonsmall Cell Lung Cancer: A Real-World Study of a Large Chinese Cohort.Semantic proximity Read ↗

A retrospective analysis of eleven gene mutations, PD-L1 expression and clinicopathological characteristics in non-small cell lung cancer patients.Semantic proximity Read ↗

Correlation between Programmed Death Ligand-1(PD-L1) Expression and Driver Gene Mutations in Non-Small Cell Lung Carcinoma- Adenocarcinoma Phenotype.Semantic proximity Read ↗

[A Real-world Study on the Assessment of Pathological Characteristics and Targeted Therapeutic Effect of Non-small Cell Lung Cancer Patients with Positive Driving Genes and High PD-L1 Expression].Semantic proximity Read ↗

PD-L1 expression in non-small cell lung carcinoma in Latin America: a systematic review and meta-analysisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.